Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Herman

Showing results (891-900 of 972) with videos related to

Pageof 98
Sort By:
Diabetes|May 17, 2018
Activation of Nrf2 Is Required for Normal and ChREBPα-Augmented Glucose-Stimulated β-Cell ProliferationAnil Kumar, Liora S Katz, Anna M Schulz, et al.
Open Forum Infectious Diseases|December 19, 2023
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 InfectionMeng Xu, Meagan P O'Brien, Andrea T Hooper, et al.
The New England Journal of Medicine|November 28, 1996
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study GroupR S Sperling, D E Shapiro, R W Coombs, et al.
Diabetes|February 2, 2020
The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 InhibitionMegan E Capozzi, Reilly W Coch, Jepchumba Koech, et al.
The Journal of Clinical Investigation|September 27, 2016
ChREBP regulates fructose-induced glucose production independently of insulin signalingMi-Sung Kim, Sarah A Krawczyk, Ludivine Doridot, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 16, 2007
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humansStella H Vincent, James R Reed, Arthur J Bergman, et al.
Journal of Clinical Microbiology|July 16, 1999
Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypesN L Michael, S A Herman, S Kwok, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 28, 2016
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver diseaseZhenghui G Jiang, Elliot B Tapper, Margery A Connelly, et al.
Particle and Fibre Toxicology|January 8, 2022
Exposure to environmentally relevant concentrations of ambient fine particulate matter (PM<sub>2.5</sub>) depletes the ovarian follicle reserve and causes sex-dependent cardiovascular changes in apolipoprotein E null miceUlrike Luderer, Jinhwan Lim, Laura Ortiz, et al.
Journal of Clinical Pharmacology|July 21, 2006
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjectsGary A Herman, Arthur Bergman, Fang Liu, et al.
Pageof 98

Showing results (891-900 of 972) with videos related to

Sort By:
Pageof 98
Diabetes|May 17, 2018
Activation of Nrf2 Is Required for Normal and ChREBPα-Augmented Glucose-Stimulated β-Cell ProliferationAnil Kumar, Liora S Katz, Anna M Schulz, et al.
Open Forum Infectious Diseases|December 19, 2023
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 InfectionMeng Xu, Meagan P O'Brien, Andrea T Hooper, et al.
The New England Journal of Medicine|November 28, 1996
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study GroupR S Sperling, D E Shapiro, R W Coombs, et al.
Diabetes|February 2, 2020
The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 InhibitionMegan E Capozzi, Reilly W Coch, Jepchumba Koech, et al.
The Journal of Clinical Investigation|September 27, 2016
ChREBP regulates fructose-induced glucose production independently of insulin signalingMi-Sung Kim, Sarah A Krawczyk, Ludivine Doridot, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 16, 2007
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humansStella H Vincent, James R Reed, Arthur J Bergman, et al.
Journal of Clinical Microbiology|July 16, 1999
Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypesN L Michael, S A Herman, S Kwok, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 28, 2016
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver diseaseZhenghui G Jiang, Elliot B Tapper, Margery A Connelly, et al.
Particle and Fibre Toxicology|January 8, 2022
Exposure to environmentally relevant concentrations of ambient fine particulate matter (PM<sub>2.5</sub>) depletes the ovarian follicle reserve and causes sex-dependent cardiovascular changes in apolipoprotein E null miceUlrike Luderer, Jinhwan Lim, Laura Ortiz, et al.
Journal of Clinical Pharmacology|July 21, 2006
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjectsGary A Herman, Arthur Bergman, Fang Liu, et al.
Pageof 98